SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to high volume and price volatility, sparking discussions around potential insider selling following a lock-up period expiration. The community is debating whether the dip represents a buying opportunity or a sign of further declines, with some citing oversold conditions and potential for a rebound. Others express concern over the company's fundamentals and the impact of potential dilution.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending as traders discuss the potential for a short squeeze, pointing to its high short interest and unusual options activity. Some believe the company's AI-driven drug discovery platform and partnerships with companies like NVDA could be a catalyst. Others remain cautious, noting concerns around cash burn and insider selling.

American Rebel Holdings, Inc. engages in the design and marketing of branded safes, and personal security and self-defense products. It also designs and manufactures branded apparel and accessories. The company was founded on December 15, 2014 and is headquartered in Brentwood, TN.

American Rebel Holdings Inc

American Rebel Holdings ($AREB) is trending amidst discussions around trading halts, potential breakout points, and the stock's history of multi-day runs. Community members are actively debating its short-squeeze potential and consolidation patterns, with some pointing to a possible 'squirt' to higher levels. Additionally, the buzz around recent biotech releases is contributing to the heightened interest in $AREB.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is trending due to a recent $75 million investment aimed at accelerating growth in AI connectivity solutions, fueling speculation about the institutional investor behind the deal. Community members are actively discussing the potential impact on the stock price, POET's strategic position in the AI hardware ecosystem, and potential M&A opportunities. Partnerships and the potential to address bottlenecks in AI data centers are also key discussion points.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential for a short squeeze and await further data, particularly regarding CAN-3110. Community talking points include speculation about upcoming news, potential partnerships, and the company's valuation relative to its pipeline. Some traders express bullish sentiment, while others remain cautious, citing past performance and concerns about management.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending amid rising gold prices, fueled by geopolitical tensions and a weakening dollar, which has some analysts predicting further gains. Community members are debating whether gold's surge indicates a broader economic downturn and whether it remains a safe haven asset given its correlation with equities. Discussions also include perspectives on inflation, potential government actions, and historical comparisons to previous market conditions.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is trending due to renewed optimism surrounding gene editing and recent insider buying, sparking community discussion about its long-term potential. Bullish sentiment is driven by advancements in CRISPR-Cas9 technology and excitement around potential applications for curing diseases. The community is closely watching for further developments and data releases that could serve as catalysts for significant price movement.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp. is trending amid discussions about its strategy to merge digital assets with oncology, specifically exploring tokenization for its mesothelioma treatment program. Community members are debating the potential of this move, with some highlighting the company's low float and others cautioning about pump-and-dump schemes. The stock's volatile price action and connection to the TON blockchain and Telegram ecosystem are also key talking points.

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Xenetic Biosciences Inc

XBIO is trending due to community discussion around its low float and potential for a short squeeze, with some traders comparing it to other recently volatile biotech stocks. Conversations mention previous gains and potential price targets, while others express concerns about dilution and the company's financial health. Recent news regarding research collaborations and financial results has also been circulating, contributing to the increased interest.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending as it approaches all-time highs, fueled by recent FDA clearance of its AI-powered cardiac imaging platform and a large NIH contract. The community is discussing its potential to break the $100 mark, with some pointing to a high short interest as a catalyst for a potential squeeze, while others are wary of its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (MyMD) a clinical stage biopharmaceutical...

PharmaCyte Biotech (NASDAQ:PMCB) Trading Down 1.6%

PharmaCyte Biotech, Inc. (NASDAQ:PMCB  Get Free Report)s stock price dropped 1.6% during mid-day trading on Tuesday . The stock traded as low as $2.34 and last traded at $2.44...

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Sees Significant Drop in Short Interest

PharmaCyte Biotech, Inc. (NASDAQ:PMCB  Get Free Report) saw a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 26,500 shares, a...

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

PharmaCyte Biotech Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

PMCB
PharmaCyte Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PMCB News

PMCB PharmaCyte Biotech Inc